Key facts
- Notable investors include Cites Startups.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Single Strand Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Single Strand Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Single Strand Biotech
Operator of a biotechnology company intended to develop next-generation synthetic oligonucleotide therapies that modulate the immune system and promote tissue regeneration. The company offers synthetic single-stranded oligonucleotide drugs designed to deliver precise, safe and long-lasting immunomodulatory effects, distinguishing itself from conventional therapies through targeted immune system regulation and tissue repair, enabling patients to access more effective, durable and safer treatments that improve quality of life and reduce reliance on less efficient existing options.
- Sector
- Healthcare
- HQ
- Sunchales, Argentina
- Founded
- 2025
- Employees
- 2
- Website
- singlestrand.com/
- Ownership
- Privately Held (backing)
Single Strand Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Single Strand Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Single Strand Biotech in its N-PORT filings yet. We sweep new filings monthly.